China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits
Executive Summary
AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.
You may also be interested in...
'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China
Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.